文献速递眼底病与葡萄膜炎

抗VEGF药物在大鼠模型中经房水外流途径的清除

Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究在大鼠脉络膜新生血管模型中单次玻璃体腔注射贝伐珠单抗、阿柏西普或雷珠单抗,用免疫荧光与共聚焦显微镜评估药物在小梁网、Schlemm管和巩膜外静脉的清除情况。三种药物均在注射后立即达峰并于48小时降至可忽略水平,虹膜角膜角清除率为98.68%至99.87%,支持作者此前否定抗VEGF聚集假说的结果。

要点

  • 三种抗VEGF药物在注射后48小时内均完全从虹膜角膜角清除。
  • 虹膜角膜角清除率介于98.68%与99.87%之间,三种药物清除模式一致。
  • 结果支持作者此前研究,否定抗VEGF在虹膜角膜角聚集的假说。

核心结论

  • 贝伐珠单抗、阿柏西普和雷珠单抗在Brown Norway大鼠单次玻璃体腔注射后48小时均从虹膜角膜角完全清除,清除率相似。
  • 这些发现支持作者此前的研究,否定抗VEGF聚集假说。

研究设计与样本

  • Brown Norway大鼠在诱导脉络膜新生血管后3天接受3微升标准浓度抗VEGF玻璃体腔注射。
  • 注射后0、3、6、24和48小时处理眼球,用共聚焦显微镜和三维重建分析评估免疫荧光,计算信号浓度和药物清除率。
  • 免疫组化过程用阴性和阳性对照组验证。

主要发现

  • 所有抗VEGF药物在小梁网、Schlemm管和巩膜外静脉的免疫荧光信号均为阳性。
  • 抗VEGF免疫染色在注射后立即达峰,然后逐渐下降至48小时可忽略水平(P < 0.05)。
  • 三种药物表现出相同模式(P > 0.05)。
  • 虹膜角膜角抗VEGF清除率在48小时介于98.68%与99.87%之间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Sustained increase in intraocular pressure (IOP) following intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of retinal disease has been theoretically attributed to aggregation of anti-VEGF in the iridocorneal angle. However, previous studies by our group showed full clearance of intravitreally injected bevacizumab, aflibercept, and ranibizumab. The objective of this study was to further analyze and compare the clearance of these anti-VEGF agents from the eye after a single injection in a rat model. METHODS: Brown Norway rats received an intravitreal injection of 3 µl anti-VEGF at the standard concentration 3 days following induction of choroidal neovascularization. The eyes were processed at 0, 3, 6, 24, and 48 hours thereafter, and immunofluorescence was evaluated with confocal microscopy and 3D reconstruction analysis. The signal concentration was calculated, and the drug clearance rate was measured. The immunohistochemistry process was validated with negative and positive control groups. RESULTS: The immunofluorescent signal was positive for all anti-VEGF agents at the trabecular meshwork, Schlemm's canal, and episcleral veins. Anti-VEGF immunostaining peaked immediately after injection and then decreased gradually to negligible at 48 hours (P < 0.05). All three agents demonstrated an identical pattern (P > 0.05). The clearance rate of anti-VEGF from the iridocorneal angle ranged between 98.68% and 99.87% at 48 hours. CONCLUSIONS: Bevacizumab, aflibercept, and ranibizumab cleared completely from the iridocorneal angle at 48 hours in the brown Norway rats following a single intravitreal injection and with similar a clearance rate. These findings support our earlier studies refuting the anti-VEGF aggregation hypothesis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ben-Arzi A, Spector I, Keshet Y, et al. Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model. Invest Ophthalmol Vis Sci. 2025. PMID: 40455045. doi:10.1167/iovs.66.6.1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。